Leonarto

22/12/2025

Before we tackle the challenges of 2026, it’s time for Series JOY 🎄
We wish you a Merry Christmas filled with moments that matter. Recharge, relax, and get ready for another year of growth together.
See you in 2026!

23/12/2024

🎄 May the magic of Christmas fill your home with warmth and happiness.
Cheers to a bright and prosperous New Year! ✨

17/04/2024

🌟 AI Hackathon in Warsaw 🌟
On 23.04, the AI Hackathon, organised by ChallengeRocket in partnership with the GPW / Giełda Papierów Wartościowych w Warszawie / Warsaw Stock Exchange , will take place in . The event will bring together talented individuals, companies with the most interesting AI projects, investors, and AI enthusiasts!

Join this unique event!
For details and registration, visit the following link:
👉 https://challengerocket.com/ai-innovators-2024 👈

Join the largest AI Hackathon in Central & Eastern Europe | ChallengeRocket.com

04/04/2024

Read the latest interview with Paweł Biernat, CTO of , published in the latest issue of Biotechnologia.pl ! Find out more about the company's latest project - 🩹transdermal insulin.

Biotts, wrocławska spółka biofarmaceutyczna, prowadzi badania, dzięki którym przesuwa dotychczasowe granice dla nośników umożliwiających aplikację lekó...

20/02/2024

Curious about the importance of genetic diagnostics in oncology and how Genomtec S.A.'s cutting-edge technology for mutation detection in oncology can help improve diagnostic access for patients?

We're delighted to invite you to a thought-provoking discussion with renowned experts who not only have extensive theoretical knowledge, but have also applied genetic diagnostics in practice.

Watch it here ➡ https://youtu.be/RHbedGaSde4?si=niG4Bu8lMv8tHZwA&t=10 ⬅

Perspektywy i rozwiązania w dziedzinie diagnostykionkologicznej w kontekście technologii rozwijanejprzez Genomtec.

02/02/2024

Great news from Biotts! The company announced the successful completion of phase 1 clinical trials for dapagliflogosin and a patent application for GLP-1 substances (products such as Ozempic, Rybelsys, Wegovy, Munjaro etc.) Will we be treating diabetes and obesity with transdermal patches in the near future? Biotts is working hard to make this an option for all!

Read the article at Biznesu and find out more

Polski start-up zamierza wejść na wielomiliardowy rynek substancji skutecznych w leczeniu cukrzycy i otyłości. Zamiast zastrzyków i tabletek proponuje plastry.

29/12/2023

We end the year 2023 with such positive news about the agreement between Genomtec S.A. and PARP for the financing of an oncology project with a value of almost 40 million PLN!
Read more in the article at the Strefa Inwestorów - Praktycznie o inwestowaniu

Spółka Genomtec, wiodąca firma z branży diagnostyki molekularnej z siedzibą we Wrocławiu (ticker GPW: GMT), podpisała w dniu 22 grudnia 2023 r. z Polską Agencją Rozwoju Przedsiębiorczości (PARP) umowę na dofinansowanie projektu „Opracowanie technologii oraz automatycznego systemu do de...

22/12/2023

The end of the year brings no greater joy than the opportunity to wish you a truly Merry Christmas! 🎄🎄🎄
May your holiday season be filled with happiness and cheer, and may the New Year bring you prosperity and success!

07/12/2023

Biotts entered into a strategic partnership with BIOTON S.A. to enhance the quality of life for individuals with diabetes by enabling them to use transdermal insulin.
Read more in the article by Mariusz Bartodziej at Puls Biznesu!

Plaster z insuliną zamiast codziennych zastrzyków – polskie firmy mogą diametralnie zmienić funkcjonowanie milionów chorych. Droga jest daleka, ale perspektywy świetne.

26/10/2023

Join a meeting with Genomtec scheduled for 27th October at 10.00 a.m. during the WSE Innovation Day!
Meet with Miron Tokarski (CEO), Charudutt Shah (CBO), and Michał Wachowski (CFO).
Register here: https://www.gpwinnovationday.pl